This drug combination could reverse Alzheimers
A highly-personalized combination treatment program reversed Alzheimer's disease symptoms in patients, according to researchers.
The Buck Institute investigators said their findings suggest the degenerative brain disease is more treatable than previously believed, United Press Internationalreported.
The study included 10 people with mild cognitive impairment, subjective cognitive impairment or Alzheimer's disease. The researchers created personalized multi-faceted treatment programs for each patient, including diet changes, exercise, improved sleep, brain stimulation, drugs and vitamins.
The patients were treated for between five and 24 months. All 10 patients showed improvements in thinking and memory, and some were even able to return to work and complete tasks that had become impossible for them as their mental abilities declined, UPI reported.
[MORE: Gene Tool Shows Promise In Curing HIV, Cancer and Autism]
"The magnitude of improvement in these 10 patients is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective," Dr. Dale Bredesen, a professor at the Buck Institute and the University of California Los Angeles, said in a news release.
"Even though we see the far-reaching implications of this success, we also realize that this is a very small study that needs to be replicated in larger numbers at various sites," Bredeson added.
[READ: New Study Suggests Alzheimer's Patients Can Store Memories]
The study in the journal Aging was small, but points to new ways to treat Alzheimer's instead of using just one or two drugs to delay declines in mental function, according to the researchers.
Their approach was inspired by some of the recent successes in using combination therapy to treat heart disease, cancer and HIV, UPI reported.
"Imagine having a roof with 36 holes in it, and your drug patched one hole very well -- the drug may have worked, a single 'hole' may have been fixed, but you still have 35 other leaks, and so the underlying process may not be affected much," Bredesen said.
"We think addressing multiple targets within the molecular network may be additive, or even synergistic, and that such a combinatorial approach may enhance drug candidate performance, as well," Bredeson explained.
Copyright © 2016 HealthDay. All rights reserved.